Skip to content

Study · Other design · 2020

6 results

Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.

van der Aart-van der Beek AB, Clegg LE, Penland RC, Boulton DW, Sjöström CD, Mentz RJ, Holman RR, Heerspink HJL

Diabetes, obesity & metabolism15 Sept 2020Cited by 31 (Europe PMC)

PMID32803900 (opens in a new tab)PMCIDPMC7756541 (opens in a new tab)DOI10.1111/dom.14175 (opens in a new tab)PepBankPUB-32803900
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanOther designEfficacy outcome

    In EXSCEL participants with baseline UACR >100 mg/g, exenatide improved eGFR slope versus placebo.

    In plain wordsIn participants with baseline UACR >100 mg/g, exenatide improved kidney filtration slope versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseeGFR slope with UACR >100 mg/g
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    eGFR slope difference versus placebo
    0.79 mL/min/1.73 m2/year
    baseline UACR >100 mg/g

    Source sentences

    Summary
    EQW improved eGFR slope assessed via mixed model repeated measures, compared with placebo, in participants with baseline UACR >100 mg/g (0.79 mL/min/1.73 m2 /year [95% confidence interval {CI} 0.24-1.34]) and UACR >200 mg/g (1.32 mL/min/1.73 m2 /year [95% CI 0.57-2.06]), but no…
    1 context sentence
    Summary · context
    We examined the effects of once-weekly exenatide (EQW) on estimated glomerular filtration rate (eGFR) slope and urinary albumin:creatinine ratio (UACR) as a function of baseline UACR
  2. 02HumanOther designEfficacy outcome

    In EXSCEL participants with baseline UACR >200 mg/g, exenatide improved eGFR slope versus placebo.

    In plain wordsIn participants with baseline UACR >200 mg/g, exenatide improved kidney filtration slope versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseeGFR slope with UACR >200 mg/g
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    eGFR slope difference versus placebo
    1.32 mL/min/1.73 m2/year
    baseline UACR >200 mg/g

    Source sentences

    Summary
    EQW improved eGFR slope assessed via mixed model repeated measures, compared with placebo, in participants with baseline UACR >100 mg/g (0.79 mL/min/1.73 m2 /year [95% confidence interval {CI} 0.24-1.34]) and UACR >200 mg/g (1.32 mL/min/1.73 m2 /year [95% CI 0.57-2.06]), but no…
    1 context sentence
    Summary · context
    We examined the effects of once-weekly exenatide (EQW) on estimated glomerular filtration rate (eGFR) slope and urinary albumin:creatinine ratio (UACR) as a function of baseline UACR
  3. 03HumanOther designEfficacy outcome

    In EXSCEL participants at lower baseline UACR thresholds, exenatide did not improve eGFR slope versus placebo.

    In plain wordsAt lower baseline UACR thresholds, exenatide did not improve kidney filtration slope versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeeGFR slope at lower UACR thresholds
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    EQW improved eGFR slope assessed via mixed model repeated measures, compared with placebo, in participants with baseline UACR >100 mg/g (0.79 mL/min/1.73 m2 /year [95% confidence interval {CI} 0.24-1.34]) and UACR >200 mg/g (1.32 mL/min/1.73 m2 /year [95% CI 0.57-2.06]), but no…
    1 context sentence
    Summary · context
    We examined the effects of once-weekly exenatide (EQW) on estimated glomerular filtration rate (eGFR) slope and urinary albumin:creatinine ratio (UACR) as a function of baseline UACR
  4. 04HumanOther designEfficacy outcome

    In EXSCEL participants with baseline UACR >30 mg/g, exenatide reduced UACR versus placebo.

    In plain wordsWith baseline UACR >30 mg/g, exenatide reduced urine albumin relative to creatinine versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseUACR with baseline UACR >30 mg/g
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    UACR reduction
    28.2%
    baseline UACR >30 mg/g

    Source sentences

    Summary
    EQW reduced UACR, compared with placebo, assessed via analysis of covariance, consistently across subgroups with baseline UACR >30 mg/g (28.2% reduction), baseline UACR >100 mg (22.5% reduction) and baseline UACR >200 mg (34.5% reduction).
    1 context sentence
    Summary · context
    We examined the effects of once-weekly exenatide (EQW) on estimated glomerular filtration rate (eGFR) slope and urinary albumin:creatinine ratio (UACR) as a function of baseline UACR
  5. 05HumanOther designEfficacy outcome

    In EXSCEL participants with baseline UACR >100 mg, exenatide reduced UACR versus placebo.

    In plain wordsWith baseline UACR >100 mg, exenatide reduced urine albumin relative to creatinine versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseUACR with baseline UACR >100 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    UACR reduction
    22.5%
    baseline UACR >100 mg

    Source sentences

    Summary
    EQW reduced UACR, compared with placebo, assessed via analysis of covariance, consistently across subgroups with baseline UACR >30 mg/g (28.2% reduction), baseline UACR >100 mg (22.5% reduction) and baseline UACR >200 mg (34.5% reduction).
    1 context sentence
    Summary · context
    We examined the effects of once-weekly exenatide (EQW) on estimated glomerular filtration rate (eGFR) slope and urinary albumin:creatinine ratio (UACR) as a function of baseline UACR
  6. 06HumanOther designEfficacy outcome

    In EXSCEL participants with baseline UACR >200 mg, exenatide reduced UACR versus placebo.

    In plain wordsWith baseline UACR >200 mg, exenatide reduced urine albumin relative to creatinine versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseUACR with baseline UACR >200 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    UACR reduction
    34.5%
    baseline UACR >200 mg

    Source sentences

    Summary
    EQW reduced UACR, compared with placebo, assessed via analysis of covariance, consistently across subgroups with baseline UACR >30 mg/g (28.2% reduction), baseline UACR >100 mg (22.5% reduction) and baseline UACR >200 mg (34.5% reduction).
    1 context sentence
    Summary · context
    We examined the effects of once-weekly exenatide (EQW) on estimated glomerular filtration rate (eGFR) slope and urinary albumin:creatinine ratio (UACR) as a function of baseline UACR

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.